Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Drug interactions between inhaled corticosteroids and enzymatic inhibitors

Drug interactions between inhaled corticosteroids and enzymatic inhibitors Eur J Clin Pharmacol (2009) 65:743–745 DOI 10.1007/s00228-009-0653-4 LETTER TO THE EDITORS Drug interactions between inhaled corticosteroids and enzymatic inhibitors Amélie Daveluy & Cécile Raignoux & Ghada Miremont-Salamé & Pierre-Olivier Girodet & Nicholas Moore & Françoise Haramburu & Mathieu Molimard Received: 10 December 2008 /Accepted: 31 March 2009 /Published online: 28 April 2009 Springer-Verlag 2009 . . . Keywords Drug interactions Fluticasone Budesonide concomitantly treated with an enzymatic inhibitor: itraco- . . Beclomethasone Cushing’s syndrome nazole (six cases), ritonavir (five cases), verapamil (two cases), and diltiazem (two cases). In adults, mean daily Adrenal insufficiency dose was lower in cases where a drug interaction was suspected [2,277 µg beclomethasone equivalent (BE) vs. Drug-drug interactions may explain an important part of the 2,883 µg BE in cases where no drug interaction was suspected; data not shown]. The delay for diagnosis ranged systemic adverse effects of inhaled corticosteroids. A recent retrospective study aimed at estimating the incidence of from less than 1 month to 16 months after initiation of the enzymatic inhibitor treatment. adrenal insufficiency in users of inhaled corticosteroids reported 46 cases (involving fluticasone, budesonide, or It is recognized that high doses of corticosteroids may induce Cushing’s syndrome, and secondary adrenal http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Pharmacology Springer Journals

Drug interactions between inhaled corticosteroids and enzymatic inhibitors

Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/drug-interactions-between-inhaled-corticosteroids-and-enzymatic-YdhGOdqtU0

References (19)

Publisher
Springer Journals
Copyright
Copyright © 2009 by Springer-Verlag
Subject
Biomedicine; Pharmacology/Toxicology
ISSN
0031-6970
eISSN
1432-1041
DOI
10.1007/s00228-009-0653-4
pmid
19399485
Publisher site
See Article on Publisher Site

Abstract

Eur J Clin Pharmacol (2009) 65:743–745 DOI 10.1007/s00228-009-0653-4 LETTER TO THE EDITORS Drug interactions between inhaled corticosteroids and enzymatic inhibitors Amélie Daveluy & Cécile Raignoux & Ghada Miremont-Salamé & Pierre-Olivier Girodet & Nicholas Moore & Françoise Haramburu & Mathieu Molimard Received: 10 December 2008 /Accepted: 31 March 2009 /Published online: 28 April 2009 Springer-Verlag 2009 . . . Keywords Drug interactions Fluticasone Budesonide concomitantly treated with an enzymatic inhibitor: itraco- . . Beclomethasone Cushing’s syndrome nazole (six cases), ritonavir (five cases), verapamil (two cases), and diltiazem (two cases). In adults, mean daily Adrenal insufficiency dose was lower in cases where a drug interaction was suspected [2,277 µg beclomethasone equivalent (BE) vs. Drug-drug interactions may explain an important part of the 2,883 µg BE in cases where no drug interaction was suspected; data not shown]. The delay for diagnosis ranged systemic adverse effects of inhaled corticosteroids. A recent retrospective study aimed at estimating the incidence of from less than 1 month to 16 months after initiation of the enzymatic inhibitor treatment. adrenal insufficiency in users of inhaled corticosteroids reported 46 cases (involving fluticasone, budesonide, or It is recognized that high doses of corticosteroids may induce Cushing’s syndrome, and secondary adrenal

Journal

European Journal of Clinical Pharmacology – Springer Journals

Published: Apr 28, 2009

There are no references for this article.